Fampridin Neuraxpharm: Uses, Dosage & Side Effects

What Is Fampridin Neuraxpharm and What Is It Used For?

Fampridin Neuraxpharm contains the active substance fampridine, also known by its chemical name 4-aminopyridine. It belongs to a class of medications called potassium channel blockers. The medicine is specifically indicated for the improvement of walking in adult patients (18 years and older) with multiple sclerosis who have walking disability, defined as an Expanded Disability Status Scale (EDSS) score of 4 to 7. This corresponds to patients who require some form of walking aid or have significant difficulty walking unaided.

Multiple sclerosis is a chronic autoimmune disease in which the immune system attacks the myelin sheath – the protective covering that surrounds nerve fibers in the brain and spinal cord. This process, called demyelination, disrupts the normal transmission of electrical signals along the nerves. As a result, patients experience a wide range of neurological symptoms, including weakness, numbness, visual disturbances, and – very commonly – difficulty walking. Walking impairment is one of the most significant and distressing symptoms of MS, affecting approximately 75% of patients at some point during the course of their disease and having a profound impact on independence, quality of life, and the ability to carry out daily activities.

The mechanism of action of fampridine is directly related to the pathophysiology of demyelination. In healthy nerve fibers, the myelin sheath acts as an insulator that speeds up the transmission of electrical impulses along the nerve (a process called saltatory conduction). When myelin is damaged or lost, potassium ions leak out through voltage-gated potassium channels that are normally covered by the myelin sheath. This leakage of potassium causes the electrical signal to weaken or fail completely, resulting in impaired nerve conduction and the clinical symptoms of MS.

Fampridine works by selectively blocking these exposed voltage-gated potassium channels on demyelinated nerve fibers. By preventing the leakage of potassium ions, fampridine helps to restore and prolong the action potential in the damaged nerve. This improved electrical signaling translates into enhanced neuromuscular function, particularly in the nerves that control leg muscles used for walking. The result is a measurable improvement in walking speed and quality for patients who respond to the treatment.

It is important to understand that not all patients with MS will benefit from fampridine. Clinical trials have consistently shown that approximately 35–43% of patients are classified as “responders,” meaning they experience a clinically meaningful improvement in walking speed as measured by the Timed 25-Foot Walk (T25FW) test. Non-responders typically do not experience significant walking improvement, which is why a trial period of 2 weeks is recommended to assess whether the medication is effective for each individual patient.

What Should You Know Before Taking Fampridin Neuraxpharm?

Contraindications

There are several important situations in which Fampridin Neuraxpharm must not be used. These absolute contraindications must be carefully evaluated before starting treatment, as violation of these restrictions can lead to serious and potentially life-threatening complications.

• Hypersensitivity: Do not take Fampridin Neuraxpharm if you are allergic to fampridine (4-aminopyridine) or any of the other ingredients in the tablet, including hypromellose, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, Opadry White (containing hypromellose, titanium dioxide, and polyethylene glycol).
• History of seizures: Fampridine must not be used in patients who have ever had a seizure (epileptic fit). Fampridine lowers the seizure threshold in a dose-dependent manner, and patients with a history of seizures are at significantly increased risk of experiencing seizures during treatment.
• Renal impairment: Fampridine is primarily excreted by the kidneys. Patients with moderate or severe kidney impairment (creatinine clearance of less than 80 mL/min) must not take this medicine, as reduced kidney function leads to higher blood levels of fampridine, which substantially increases the risk of seizures and other adverse effects.
• Concurrent use of other fampridine-containing medicines: Fampridine must not be used together with any other medicinal product that contains fampridine (4-aminopyridine). This includes compounded formulations of 4-aminopyridine that may be available in some countries. Using multiple sources of fampridine simultaneously increases the risk of overdose and seizures.

Warnings and Precautions

Beyond the absolute contraindications listed above, there are several important warnings and precautions that your doctor should consider before prescribing Fampridin Neuraxpharm and that you should be aware of during treatment.

• Kidney function monitoring: Because fampridine is cleared from the body through the kidneys, your doctor should check your kidney function (creatinine clearance) before starting treatment and regularly during treatment, especially if you are elderly or taking other medications that may affect kidney function. Even mild renal impairment can increase fampridine blood levels and may require dose adjustment or closer monitoring.
• Cardiac arrhythmias: Use caution if you have a history of heart rhythm disorders (arrhythmias). Fampridine may affect cardiac conduction in some patients. Patients with cardiac conditions should discuss risks and benefits with their prescribing physician.
• Infections: Urinary tract infections are more common in patients taking fampridine. Be alert for symptoms such as frequent urination, burning sensation during urination, or cloudy urine, and report these to your doctor promptly.
• Dizziness and balance disturbance: Fampridine can cause dizziness, vertigo, and balance problems. These symptoms increase the risk of falls, which is particularly concerning in MS patients who already have impaired mobility. Exercise caution when walking, using stairs, or operating machinery until you know how this medicine affects you.
• Allergic reactions: Serious allergic reactions (anaphylaxis) have been reported in patients taking fampridine. Seek immediate medical attention if you develop symptoms such as swelling of the face, lips, tongue, or throat; difficulty breathing; hives; or rapid heartbeat.
• Trigeminal neuralgia: Cases of trigeminal neuralgia (severe facial pain) have been reported. If you develop new or worsening facial pain, inform your doctor.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, ask your doctor for advice before taking this medicine. Fampridin Neuraxpharm is not recommended during pregnancy. There are limited data on the use of fampridine in pregnant women. Animal studies have shown some reproductive toxicity at doses higher than the recommended human dose. The potential risk to a human fetus is unknown, and therefore fampridine should only be used during pregnancy if clearly necessary and if the potential benefit justifies the potential risk to the fetus.

It is not known whether fampridine is excreted in human breast milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants, a decision must be made whether to discontinue breastfeeding or to discontinue fampridine, taking into account the importance of the medicine to the mother. Your doctor will help you weigh these considerations.

There is no data on the effect of fampridine on human fertility. Animal studies have not shown effects on fertility at therapeutic doses. However, if you are concerned about fertility, discuss this with your doctor before starting treatment.

How Does Fampridin Neuraxpharm Interact with Other Drugs?

Drug interactions with fampridine are primarily related to its elimination pathway through the kidneys. Fampridine is excreted largely unchanged via the kidneys, with approximately 90% of the dose recovered in the urine. A significant portion of this renal elimination occurs via active tubular secretion through the organic cation transporter 2 (OCT2). Any drug that inhibits OCT2 or reduces overall renal function has the potential to increase fampridine plasma concentrations, which in turn increases the risk of dose-dependent adverse effects, particularly seizures.

Additionally, fampridine itself is a weak inhibitor of OCT2, which means it has the theoretical potential to affect the elimination of other drugs that are substrates for this transporter. Although this effect is considered unlikely at therapeutic doses, it is an area of ongoing pharmacological investigation.

No formal interaction studies have been conducted with fampridine and disease-modifying therapies for MS (such as interferons, glatiramer acetate, natalizumab, or fingolimod). In clinical trials, fampridine was used in combination with these DMTs without any apparent increase in adverse effects, and concurrent use is generally considered acceptable. However, as with any combination of medications, inform your doctor about all treatments you are receiving.

Major Interactions

Minor Interactions

What Is the Correct Dosage of Fampridin Neuraxpharm?

The dosing of Fampridin Neuraxpharm is straightforward but must be followed precisely. The prolonged-release formulation is specifically designed to release fampridine slowly over several hours, maintaining therapeutic blood levels while avoiding the dangerously high peak concentrations that would occur with immediate-release formulations. This controlled release is critical for both efficacy and safety, particularly in relation to the dose-dependent seizure risk.

Adults

Treatment should be started by a doctor experienced in treating multiple sclerosis. After starting Fampridin Neuraxpharm, the walking improvement should be assessed after 2 weeks of treatment. The assessment is typically performed using a walking test such as the Timed 25-Foot Walk (T25FW) or by clinical evaluation of walking quality. If no improvement is observed within this timeframe, the medication should be discontinued, as continuing treatment is unlikely to provide benefit.

For patients who do respond to treatment, ongoing periodic assessments of walking ability are recommended, typically every 6 to 12 months. If the walking benefit is no longer evident at any point during treatment, the physician should consider stopping the medication.

Children and Adolescents

Elderly Patients

Elderly patients are at particular risk because age-related decline in kidney function is common and may not be detected by serum creatinine levels alone. The creatinine clearance should be calculated using an appropriate formula (such as the Cockcroft-Gault equation) to obtain an accurate estimate of renal function. Regular monitoring is essential throughout treatment in this population.

Missed Dose

If you forget to take a dose, do not take a double dose to make up for the missed one. Simply skip the missed dose and take the next dose at the regular time. It is important to always maintain a gap of approximately 12 hours between doses. Taking two doses too close together increases the risk of side effects, particularly seizures, because it can cause the blood level of fampridine to rise to dangerous levels.

Overdose

There is no specific antidote for fampridine overdose. Treatment is supportive and symptomatic. In clinical overdose cases, seizures have been the most prominent and dangerous symptom. The severity of overdose effects is directly related to the dose taken. Doses above 20 mg per day have been associated with a significantly higher incidence of seizures in clinical studies. Hemodialysis has been shown to effectively remove fampridine from the blood and may be considered in severe overdose cases.

What Are the Side Effects of Fampridin Neuraxpharm?

Like all medicines, Fampridin Neuraxpharm can cause side effects, although not everybody experiences them. The side effects observed during clinical trials and post-marketing surveillance are presented below, organized by frequency. Understanding the frequency categories helps put the risks into perspective: “very common” means the side effect occurs in more than 1 in 10 patients, “common” means 1 in 10 to 1 in 100 patients, “uncommon” means 1 in 100 to 1 in 1,000 patients, and “rare” means fewer than 1 in 1,000 patients.

The overall safety profile of fampridine at the recommended dose of 10 mg twice daily is considered acceptable for most patients. Many side effects are mild to moderate in intensity and tend to improve as treatment continues. However, certain side effects – particularly seizures – are serious and require immediate medical attention and permanent discontinuation of the medication.

The relationship between dose and seizure risk is well-established. At the approved dose of 10 mg twice daily, seizures are uncommon. However, at doses exceeding 10 mg twice daily, the incidence of seizures rises substantially. This is why it is absolutely critical to never exceed the recommended dosage, to maintain the 12-hour interval between doses, and to never crush or break the prolonged-release tablet (which would cause a rapid release of the full dose).

Urinary tract infections, the most common side effect, are also a common complication of MS itself, so it can be difficult to determine whether they are caused by the medication or by the underlying disease. MS patients often have impaired bladder function (neurogenic bladder) that predisposes them to urinary infections regardless of fampridine use. Maintaining adequate hydration and practicing good urinary hygiene can help reduce this risk.

If you experience any side effects that concern you or that are not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you contribute to providing more information on the safety of this medicine.

How Should You Store Fampridin Neuraxpharm?

Proper storage of Fampridin Neuraxpharm is essential to ensure the medication remains effective and safe throughout its shelf life. The prolonged-release tablet formulation is designed to release fampridine at a controlled rate; if the tablets are damaged by improper storage conditions (such as exposure to excessive moisture or heat), the release mechanism may be compromised, potentially leading to a rapid release of the active ingredient and an increased risk of adverse effects.

• Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
• Light protection: Keep the tablets in the original packaging (blister pack or bottle) to protect from light.
• Moisture protection: Keep the tablets in the original packaging to protect from moisture. If the tablets come in a bottle, keep the bottle tightly closed and leave the desiccant sachet inside the bottle.
• Child safety: Keep out of the sight and reach of children. The consequences of accidental ingestion by a child could be serious, particularly the risk of seizures.
• Expiry date: Do not use Fampridin Neuraxpharm after the expiry date stated on the blister, bottle, and outer carton. The expiry date refers to the last day of that month.
• Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help to protect the environment.

If you notice that the tablets have changed in appearance (for example, discoloration, crumbling, or visible damage), do not take them and consult your pharmacist for a replacement. An intact prolonged-release tablet should be white to off-white, oval-shaped, and biconvex, with smooth surfaces and no cracks or chips.

What Does Fampridin Neuraxpharm Contain?

Understanding the full composition of a medication is important for identifying potential allergens and understanding the tablet’s formulation. Fampridin Neuraxpharm is formulated as a prolonged-release tablet, meaning the tablet matrix is specifically engineered to slowly release the active ingredient over several hours as it passes through the gastrointestinal tract.

Active Ingredient

Each prolonged-release tablet contains 10 mg of fampridine (also known as 4-aminopyridine, or 4-AP). Fampridine is a small organic molecule with the molecular formula C₅H₆N₂ and a molecular weight of 94.11 g/mol. It is a white to off-white crystalline powder that is freely soluble in water.

Other Ingredients (Excipients)

The other ingredients in the tablet serve important functions in the manufacturing process, the prolonged-release mechanism, and the stability of the medication:

• Hypromellose (HPMC): Forms the matrix of the prolonged-release system. This polymer swells upon contact with gastric fluid and controls the rate at which fampridine is released from the tablet.
• Microcrystalline cellulose: Used as a filler and binder to give the tablet its shape and mechanical strength.
• Colloidal anhydrous silica: A flow agent that ensures uniform mixing of ingredients during manufacturing.
• Magnesium stearate: A lubricant that prevents the tablet from sticking to the manufacturing equipment during the compression process.
• Film-coating (Opadry White): Contains hypromellose, titanium dioxide (E171), and polyethylene glycol (macrogol). The coating protects the tablet, makes it easier to swallow, and provides the characteristic white appearance.

The tablet is white to off-white, oval-shaped, biconvex, and approximately 13 mm long. It does not have a score line because the tablet must never be broken or divided – doing so would destroy the prolonged-release mechanism and cause the entire dose to be released at once.

References

1. European Medicines Agency (EMA). Fampyra (fampridine) – Summary of Product Characteristics. Last updated 2024. Available at: www.ema.europa.eu
2. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. The Lancet. 2009;373(9665):732–738. doi:10.1016/S0140-6736(09)60442-6
3. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology. 2010;68(4):494–502. doi:10.1002/ana.22240
4. U.S. Food and Drug Administration (FDA). Ampyra (dalfampridine) – Prescribing Information. Reference ID: 4828913. Available at: www.fda.gov
5. National Institute for Health and Care Excellence (NICE). Fampridine for improving walking in people with multiple sclerosis. Technology appraisal guidance [TA832]. 2022.
6. Ruck T, Bittner S, Simon OJ, et al. Long-term effects of dalfampridine in patients with multiple sclerosis. Journal of the Neurological Sciences. 2014;337(1–2):18–24. doi:10.1016/j.jns.2013.11.007
7. Hobart J, Blight AR, Goodman A, et al. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509–1517. doi:10.1212/WNL.0b013e31828cf7f3
8. World Health Organization (WHO). Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
9. Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. The Lancet. 2018;391(10130):1622–1636. doi:10.1016/S0140-6736(18)30481-1
10. Mehta LR, Schwid SR, Arnold DL, et al. Communicating the risk of seizures associated with fampridine (Fampyra) treatment. Therapeutic Advances in Drug Safety. 2015;6(6):225–231.

Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in neurology, pharmacology, and internal medicine.

All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.